165 related articles for article (PubMed ID: 15291652)
41. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
[TBL] [Abstract][Full Text] [Related]
42. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
44. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
Achilla E; McCrone P
Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
[TBL] [Abstract][Full Text] [Related]
45. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
[TBL] [Abstract][Full Text] [Related]
46. Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia.
Jin H; Tappenden P; Robinson S; Achilla E; Aceituno D; Byford S
PLoS One; 2020; 15(7):e0234996. PubMed ID: 32649663
[TBL] [Abstract][Full Text] [Related]
47. Treatment of schizophrenia: let's talk dollars and sense.
Buckley PF
Am J Manag Care; 1998 Mar; 4(3):369-83. PubMed ID: 10178499
[TBL] [Abstract][Full Text] [Related]
48. The cost of relapse and the predictors of relapse in the treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries DE; Salkever D; Slade EP; Peng X; Conley RR
BMC Psychiatry; 2010 Jan; 10():2. PubMed ID: 20059765
[TBL] [Abstract][Full Text] [Related]
49. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.
Correll CU; Maayan L; Kane J; Hert MD; Cohen D
J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.
Hargreaves WA; Gibson PJ
CNS Drugs; 2005; 19(5):393-410. PubMed ID: 15907151
[TBL] [Abstract][Full Text] [Related]
51. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Heinrichs RW
Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
[No Abstract] [Full Text] [Related]
52. [Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics].
Laux G; Günther W
Pharm Unserer Zeit; 2002; 31(6):572-6. PubMed ID: 12481515
[No Abstract] [Full Text] [Related]
53. Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
Law WL; Hui HY; Young WM; You JH
Int J Clin Pharmacol Ther; 2007 May; 45(5):264-70. PubMed ID: 17542348
[TBL] [Abstract][Full Text] [Related]
54. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
Glazer WM; Ereshefsky L
J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
[TBL] [Abstract][Full Text] [Related]
55. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
58. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
Citrome L
Int J Clin Pract; 2010 Jan; 64(2):216-39. PubMed ID: 19886879
[TBL] [Abstract][Full Text] [Related]
59. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
60. Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study.
Cortesi PA; Mencacci C; Luigi F; Pirfo E; Berto P; Sturkenboom MC; Lopes FL; Giustra MG; Mantovani LG; Scalone L
BMC Psychiatry; 2013 Mar; 13():98. PubMed ID: 23522406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
